PMA 411R

Next Previous
Drug Profile

PMA 411R

Alternative Names: PMA-411R

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmedartis
  • Class Anti-inflammatories; Antineoplastics; Skin disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Inflammation; Leukaemia; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 18 Jul 2016 PMA 411R is still in preclinical development for Leukaemia, Solid tumours, Inflammation, Rheumatoid arthritis and Atopic dermatitis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top